(UroToday.com) In a podium presentation in the Renal Cancer I – Localized session at the 19th Meeting of the EAU Section of Oncological Urology, Dr. Giusti presented on advances in conservative treatment approaches in patients with upper tract urothelial carcinoma (UTUC). He began by emphasizing that conservative treatment should be preferred for patients with low-grade disease […]
(UroToday.com) The 2022 EAU Section of Oncological Urology (ESOU) Annual Meeting included a session on urothelial cancer and a presentation by Dr. Valeria Panebianco discussing how magnetic resonance imaging (MRI) has changed the bladder cancer pathway. Dr. Panebianco notes that for more than 30 years the diagnostic pathways for bladder cancer patients have remained largely unchanged, […]
(UroToday.com) In a podium presentation in the Renal Cancer I – Localized session at the 19th Meeting of the EAU Section of Oncological Urology, Dr. Masson-Lecomte presented on the selection of patients for early cystectomy, based on results of the BRAVO trial.
(UroToday.com) In a podium presentation in the Renal Cancer I – Localized session at the 19th Meeting of the EAU Section of Oncological Urology, Dr. Porpiglia presented on the role of augmented reality in robotic assisted partial nephrectomy. He began by defining, in this context, augmented reality as the superimposition of 3-dimensional (3D) virtual models over […]
(UroToday.com) In a podium presentation in the Renal Cancer I – Localized session at the 2022 EAU Section of Oncological Urology (ESOU) Annual Meeting, Dr. Volpe presented on the role of artificial intelligence in kidney cancer diagnosis.
(UroToday.com) The 2022 EAU Section of Oncological Urology (ESOU) Annual Meeting included a session on localized prostate cancer and a state-of-the-art lecture by Dr. Daniel Spratt discussing molecular advances in risk stratification of localized disease. Dr. Spratt notes that treatment decisions at their core are dominated by risk stratification, with the earliest risk stratification dating back […]
Treatment of B-cell malignancies with CD19-directed chimeric antigen receptor (CAR) T-cells marked a new era in immunotherapy, which yet has to be successfully adopted to solid cancers. Epigenetic inhibitors of DNA methyltransferases (DNMTi) and histone deacetylases (HDACi) can induce broad changes in gene expression of malignant cells, thus making these inhibitors interesting combination partners for […]
Immune-modulating systemic therapies are often used to treat advanced cancer such as metastatic clear cell renal cell carcinoma (ccRCC). Used alone, sequence-based biomarkers neither accurately capture patient dynamics nor the tumor immune microenvironment.
Interleukin-1α (IL-1α) is thought to play a major role in renal cell carcinoma (RCC), but the specific mechanism is unclear. In this study, we explored the potential mechanism of the role of IL-1α in RCC.
In 2018, the US Preventive Services Task Force recommended that PSA screening for prostate cancer involve men aged 55-69, based on a personal decision following consultation with a health professional.
